| Name | Title | Contact Details |
|---|
During its 20-plus-year history, MVB Bank has grown from a community bank with 35 employees to a forward-thinking, NASDAQ-listed, Russell 2000® company with more than 400 Team Members living in more than 25 different states. Headquartered in Fairmont, West Virginia, MVB Bank and the Banks subsidiaries, the MVB Community Development Corp., Chartwell Compliance, Paladin and Trabian, provide financial services to individuals and corporate clients in the Mid-Atlantic region and beyond. MVB Financial Corp., the holding company of MVB Bank, is publicly traded on The Nasdaq Capital Market under the ticker "MVBF."
DistroKid is a digital music distribution service based in the United States, founded in 2013 by Philip Kaplan. It emerged from a social media platform for musicians called Fandalism. DistroKid specializes in helping independent artists and labels distribute their music to major online retailers, including Spotify, Apple Music, Amazon Music, and YouTube Music. The company offers a range of services to support musicians, including music distribution, monetization of sales and streams, and metadata customization. DistroKid also provides storage solutions for music files and additional features like customized YouTube URLs and Digital Object Identifiers (DOIs). With a competitive pricing model, artists can upload unlimited songs and albums for an annual fee, while retaining 100% of their earnings. DistroKid has been utilized by various notable artists, showcasing its effectiveness in the DIY music distribution space.
SEFCU is a New York-based financial institution that provides personal and commercial banking products and services for individuals and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
With 20+ years of collective experience, OeP helps brands capitalize on Amazons growth, using data-driven strategies executed by experts, enabled by technology, and aligned with Amazons dynamic platform and KPIs.